DexCom/$DXCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
$DXCM
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
10,250
ISIN
US2521311074
Website
DexCom Metrics
BasicAdvanced
$34B
64.15
$1.33
1.45
-
Price and volume
Market cap
$34B
Beta
1.45
52-week high
$117.19
52-week low
$57.52
Average daily volume
3.5M
Financial strength
Current ratio
1.499
Quick ratio
1.275
Long term debt to equity
57.253
Total debt to equity
111.427
Interest coverage (TTM)
26.69%
Profitability
EBITDA (TTM)
857.8
Gross margin (TTM)
59.43%
Net profit margin (TTM)
12.90%
Operating margin (TTM)
15.25%
Effective tax rate (TTM)
26.77%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
5.98%
Return on equity (TTM)
23.72%
Valuation
Price to earnings (TTM)
64.154
Price to revenue (TTM)
8.114
Price to book
14.78
Price to tangible book (TTM)
15.6
Price to free cash flow (TTM)
58.512
Free cash flow yield (TTM)
1.71%
Free cash flow per share (TTM)
146.05%
Growth
Revenue change (TTM)
9.11%
Earnings per share change (TTM)
-13.32%
3-year revenue growth (CAGR)
17.27%
10-year revenue growth (CAGR)
30.71%
3-year earnings per share growth (CAGR)
28.60%
10-year earnings per share growth (CAGR)
33.39%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
Bulls say / Bears say
DexCom's G7 Continuous Glucose Monitoring (CGM) system received FDA approval in April 2025, featuring a 15-day wear time and enhanced user convenience, positioning the company to capture a larger market share. (Monexa)
The launch of Stelo, an over-the-counter glucose sensor approved in March 2024 for non-insulin-using Type 2 diabetes patients, opens a significant new market segment for DexCom. (Nasdaq)
DexCom's integration of the G7 system with Insulet's Omnipod 5 insulin delivery system and direct connectivity to the Apple Watch enhances its product ecosystem, potentially increasing user adoption. (Monexa)
DexCom's operating income for Q3 2024 decreased to $152.0 million from $205.5 million in the same period the previous year, indicating pressure on profit margins. (GuruFocus)
The company faces increased competition from Abbott and Medtronic, with Abbott's FreeStyle Libre 3 receiving expanded Medicare coverage in June 2025, potentially impacting DexCom's market share. (Monexa)
DexCom's total debt increased from $2.09 billion in 2022 to $2.59 billion in 2023, with a debt-to-EBITDA ratio of 2.1x, which could limit financial flexibility for future investments. (Monexa)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
DexCom News
AllArticlesVideos
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
GlobeNewsWire·2 days ago
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
Investors Business Daily·1 week ago
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $34B as of July 11, 2025.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 64.15 as of July 11, 2025.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.